Trilaciclib is under clinical development by Pharmacosmos and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase III drugs for Triple-Negative Breast Cancer (TNBC) have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Trilaciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trilaciclib overview
Trilaciclib (Cosela) is a potential antineoplastic agent with chemoprotective properties. It is formulated as lyophilized cake for solution for intravenous route of administration. Cosela is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).
Trilaciclib is under development for the treatment of small-cell lung cancer, metastatic triple negative breast cancer, colon cancer, castrate-resistant prostate cancer, NSCLC as first line and chemotherapy-induced myelosuppression. It is administered through intravenous route. The drug candidate acts by targeting cyclin-dependent kinases (CDK) 4 and 6. It was also under development for the treatment of non-small cell lung cancer, metastatic colorectal cancer and metastatic bladder cancer (locally advanced or metastatic urothelial carcinoma).
Pharmacosmos overview
Pharmacosmos is a pharmaceutical company. It specializes in carbohydrate chemistry and the development of treatments for blood diseases, particularly iron deficiency and anaemia. The company’s products include innovative treatments for iron deficiency and iron deficiency anaemia, as well as glucose poly- and oligosaccharides and their derivatives for pharmaceutical, high-tech, and medical use. Pharmacosmos also carries out veterinary medicine, producing ferric hydroxide complex for animal health. Its products serve patients suffering from iron-related conditions and are used in various medical and veterinary applications. The company operates in Denmark and the UK. Pharmacosmos is headquartered in Holbaek, Denmark.
For a complete picture of Trilaciclib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
